10-K: OPKO Health Reports Wider Net Loss in 2025 Amid Strategic Shifts

OPKO Health, Inc. reported a significantly wider net loss of $225.7 million in 2025, despite an improved operating loss and strategic divestitures aimed at streamlining its diagnostics business.

Summary

• OPKO Health, Inc. is a diversified healthcare company with pharmaceutical and diagnostics segments.
• The company reported a net loss of $225.7 million for the year ended December 31, 2025, compared to a net loss of $53.2 million in 2024.
• Operating loss improved to $117.4 million in 2025 from $152.1 million in 2024.
• Total revenues decreased by 15% to $606.9 million in 2025 from $713.1 million in 2024, primarily due to divestitures in the diagnostics segment.
• Revenue from services in the diagnostics segment decreased by 23% ($110.4 million) in 2025, mainly due to the sale of BioReference's lab and oncology operations.
• Pharmaceutical product revenue increased by 1% ($1.8 million) to $156.9 million in 2025, driven by favorable foreign exchange impacts and a $0.8 million increase in Rayaldee revenue to $29.8 million.
• Revenue from intellectual property and other increased by 3% ($2.3 million) to $79.7 million in 2025, boosted by the BARDA Contract, Eli Lilly royalties, and a Regeneron upfront payment, partially offset by the absence of a Merck milestone payment from 2024.
• Research and development expenses increased by 18% to $124.0 million in 2025, primarily due to higher manufacturing expenses for biological products and increased headcount at ModeX Therapeutics.
• Selling, general and administrative expenses decreased by 27% to $223.0 million in 2025, largely due to lower employee-related expenses and operational efficiencies following divestitures.
• The company completed the sale of its oncology diagnostics business and related clinical testing assets to Labcorp in September 2025 for up to $225 million, including $32.5 million in potential earnout consideration.
• A gain of $101.6 million was recognized from the oncology transaction in 2025, following a $121.5 million gain from the BioReference transaction in 2024.
• Interest expense significantly increased to $108.5 million in 2025 from $47.5 million in 2024, mainly due to the amortization of debt discount and debt issuance costs related to the 2044 Notes and 2029 Convertible Notes.
• Other income (expense), net swung from $206.9 million income in 2024 to ($29.9 million) expense in 2025, primarily due to the absence of large gains from the GeneDx investment seen in 2024 and a $32.6 million inducement expense related to Note Exchange Transactions.
• Cash, cash equivalents, and restricted cash stood at $382.7 million as of December 31, 2025.
• The company repurchased 34,557,844 shares of Common Stock for approximately $47.0 million in 2025 under its $200.0 million repurchase program.
• An amendment to the collaboration and license agreement with Entera Bio Ltd. was made in February 2026 to include the development of an oral long-acting PTH tablet for hypoparathyroidism, with development costs shared equally.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a slightly negative sentiment. While strategic divestitures and pipeline advancements show long-term potential, the significant increase in net loss and substantial interest expense raise immediate financial concerns, overshadowing operational improvements.

Positives

• Operating loss improved by 23% to $117.4 million in 2025 from $152.1 million in 2024, indicating better operational efficiency.
• Strategic divestitures of non-core laboratory assets to Labcorp generated significant cash proceeds and gains on sale ($101.6 million in 2025, $121.5 million in 2024).
• NGENLA (Somatrogon) has secured marketing authorizations in over 50 markets worldwide, including the U.S., EU, Japan, Canada, and Australia, and contributed $31.9 million in royalty and gross profit share payments in 2025.
• Rayaldee revenue increased by $0.8 million to $29.8 million in 2025, with marketing authorizations in 11 European countries and commercial launch in Macau.
• The 4Kscore test revenue increased by over 13% year-over-year in 2025, supported by a 2025 FDA label expansion allowing testing without a digital rectal examination (DRE), broadening its market.
• ModeX Therapeutics is advancing a robust early-stage pipeline of multi-specific immune therapies for cancer and infectious diseases, including MDX2001 (Phase 1 advanced to fifth dose level), MDX2003 (Phase 1 expected in early 2026), and MDX2004 (first patient dosed in October 2025).
• ModeX was awarded a BARDA contract, which contributed $28.5 million in revenue in 2025, for advancing a platform and product candidates addressing viral infectious diseases.
• A strategic license and collaboration agreement with Regeneron Pharmaceuticals, Inc. was entered into in October 2025 for multispecific antibodies, with ModeX receiving an upfront payment of $7.0 million and potential future milestones exceeding $1.0 billion.
• EirGen Pharma Ltd. launched a new advanced manufacturing facility in late 2025, estimated to double its annual output capacity to approximately 1 billion units by 2027.
• The company repurchased $47.0 million of Common Stock in 2025 under its $200.0 million program, demonstrating a commitment to shareholder returns.
• The expanded partnership with Entera Bio Ltd. for an oral long-acting parathyroid hormone (LA-PTH) analog represents a promising new development program.

Negatives

• Net loss significantly widened to $225.7 million in 2025 from $53.2 million in 2024, primarily due to increased interest expense and a swing in other income/expense.
• Total revenues decreased by 15% to $606.9 million in 2025, largely due to the divestiture of BioReference's non-core assets.
• Interest expense more than doubled to $108.5 million in 2025 from $47.5 million in 2024, driven by debt amortization and interest on new notes.
• Other income (expense), net, shifted from a $206.9 million income in 2024 to a $29.9 million expense in 2025, mainly due to the absence of significant gains from the GeneDx investment and a $32.6 million inducement expense.
• Research and development expenses increased by 18% to $124.0 million in 2025, contributing to the overall loss.
• The company has a history of operating losses and may not achieve profitability in the near future.
• No dividends have been paid to common stock holders since incorporation, and none are anticipated in the foreseeable future.
• The Israel Tax Authority issued an assessment of approximately $246 million (including interest) against OPKO Biologics for tax years 2014-2020, which is currently under appeal and could have a material adverse effect if unresolved favorably.

Risks

• History of operating losses and uncertainty of achieving sustained profitability or positive cash flow.
• Need for, and ability to obtain, additional financing on favorable terms or at all, which could lead to dilution or restrictive debt covenants.
• Adverse results in material litigation matters or governmental inquiries, such as the Israel Tax Authority assessment.
• Inherent risks in developing, obtaining regulatory approvals for, and commercializing new products; research and development activities may not result in commercially viable products.
• Earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results.
• Inability to generate or sustain profits or cash flow from laboratory operations or substantial revenue from NGENLA, Rayaldee, and other products.
• Ability to manage changing operations, including integration challenges for acquired businesses.
• Uncertainty that products in ModeX Therapeutics' R&D pipeline will ultimately be commercialized.
• Competition from currently available over-the-counter and prescription products, as well as products under development by others, that may be more effective or less expensive.
• Ability to comply with regulatory requirements regarding sales, marketing, and manufacturing of products and operation of laboratories.
• Performance of third-party vendors, distribution partners, licensees, and manufacturers over which the company has limited control.
• Changes in regulation and policies, including increasing downward pressure on healthcare reimbursement.
• Increased competition, including price competition, in both pharmaceutical and diagnostic testing industries.
• Success is dependent on the involvement and continued efforts of Chairman and CEO, Phillip Frost, M.D.; loss of his services or damage to his reputation could adversely affect the business.
• Changing relationships with payors, suppliers, and strategic partners.
• Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services.
• Ability to maintain reimbursement coverage for products and services, including Rayaldee and the 4Kscore test.
• Failure to timely or accurately bill and collect for services, leading to non-payment or recoupments.
• Information technology systems may be subject to unauthorized tampering, cyberattack, or other data security or privacy incidents, potentially impacting billing or disrupting operations.
• Failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients.
• Failure to establish and perform to appropriate quality standards in testing services.
• Failure to maintain the security of patient-related information or compliance with security requirements.
• Ability to obtain and maintain intellectual property protection for products and defend intellectual property rights without infringing on others' rights.
• Ability to attract and retain key scientific and management personnel.
• Risk that the carrying value of certain assets (goodwill and intangible assets) may exceed fair value, causing impairment charges.
• Ability to comply with the terms of the 2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services.
• Failure to obtain and maintain regulatory approval for products and services outside the U.S.
• Legal, economic, political, regulatory, currency exchange, and other risks associated with international operations, including potential instability in Israel.
• Disruptions to operations, including impact on employees and business continuity, from ongoing tensions in the Middle East.
• The regulatory approval process is expensive, time-consuming, and uncertain, potentially preventing commercialization of product candidates.
• Market may not be receptive to products even after regulatory approval, affecting revenue generation.
• Failure to comply with complex and rapidly evolving laws and regulations (e.g., HIPAA, GDPR, Anti-Kickback, Stark Law, False Claims Act) could result in penalties, damages, or operational changes.
• Changes in regulation and policies, including increasing downward pressure on healthcare reimbursement (e.g., PAMA), may adversely affect profitability.
• A significant short position in Common Stock could cause substantial downward pressure and volatility in the stock price.
• Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act, especially for acquired companies, could harm business and operating results.

Future Outlook

The company aims to build a leading portfolio of next-generation therapies and diagnostics by advancing the ModeX multispecific pipeline, expanding its portfolio through strategic collaborations, maximizing the global value of NGENLA, executing on Rayaldee's international expansion, and optimizing specialty diagnostics, particularly the 4Kscore test. It expects to complete IND-enabling work and initiate a Phase 1 study for injectable OPK-88006 in 2026, and file an IND application for the oral LA-PTH tablet in late 2026. The global hGH market is expected to expand by up to 12.3% annually through 2030, positioning NGENLA for significant market share. EirGen's new manufacturing facility is estimated to double annual output capacity to approximately 1 billion units by 2027. The company believes its cash on hand is sufficient to meet anticipated cash requirements for operations and debt service beyond the next 12 months.

Management Comments

• Our highly experienced management team, with extensive development, regulatory and commercialization expertise, provides us with the necessary leadership to capitalize on these diverse commercial opportunities.
• We believe our highly experienced management team, with extensive development, regulatory and commercialization expertise, provides us with the necessary leadership to capitalize on these diverse commercial opportunities.
• We believe NGENLA is positioned to gain significant worldwide share as the market consolidates from seven daily treatments to three long-acting therapies that offer improved patient adherence.
• We believe that the cash, cash equivalents and restricted cash on hand on December 31, 2025 are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months.

Industry Context

StockSavvy.ai notes that OPKO Health's strategic divestitures of non-core diagnostics assets align with a broader industry trend of healthcare companies streamlining operations to focus on high-margin specialty areas and innovative therapies. The increased R&D investment in ModeX Therapeutics' multi-specific immune therapies reflects the growing industry focus on advanced oncology and infectious disease treatments. The expansion of NGENLA's global market presence and Rayaldee's international strategy positions OPKO within the competitive pharmaceutical landscape, where long-acting therapies and targeted treatments are gaining traction. The 4Kscore test's FDA label expansion is a significant competitive advantage in the prostate cancer diagnostics market, which is increasingly valuing non-invasive and accurate screening methods. The substantial increase in interest expense and the swing in other income highlight the financial pressures and volatility inherent in the biotech and diagnostics sectors, particularly for companies in development stages or undergoing significant restructuring.

Comparison to Industry Standards

• NGENLA (Somatrogon) competes in the global human growth hormone (hGH) market, valued at approximately $7.4 billion in 2024 and projected to grow by up to 12.3% annually through 2030. Its once-weekly injection offers improved patient adherence compared to daily somatropin treatments, such as Pfizer's Genotropin, and positions it favorably against other long-acting therapies from competitors like Ascendis Pharma A/S and Novo Nordisk A/S.
• Rayaldee competes with activated vitamin D analogs (e.g., calcitriol, doxercalciferol, paricalcitol) and vitamin D supplements (e.g., ergocalciferol, cholecalciferol) for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients. The company believes Rayaldee offers substantial benefits over these, but faces competition from lower-priced products and larger pharmaceutical companies.
• The 4Kscore test, a prostate cancer biomarker test, is recommended by the National Comprehensive Cancer Network (NCCN) and the European Association of Urology (EAU), indicating strong clinical validation and acceptance compared to standard PSA tests. Its FDA label expansion to allow use without a digital rectal examination (DRE) significantly broadens its potential market, particularly among primary care providers, differentiating it from competitors in the urology diagnostics space.
• ModeX Therapeutics' pipeline of multi-specific immune therapies for cancer and infectious diseases, leveraging the MSTAR platform, positions OPKO in a highly competitive and rapidly evolving biotechnology sector. Collaborations with industry leaders like Merck and Regeneron are critical for sharing development costs and leveraging global infrastructure, a common strategy for smaller biotech firms to compete with larger pharmaceutical players.

Corporate Governance

Legal Proceedings

• The Israel Tax Authority (ITA) issued an assessment of approximately $246 million (including interest) against OPKO Biologics related to uncertain tax positions for the 2014-2020 tax years. The company has appealed this assessment, believing the issues are without technical merit, and intends to exhaust all judicial remedies.
• The company and BioReference entered into a Settlement Agreement and Corporate Integrity Agreement (CIA) in July 2022 to resolve an investigation and civil action concerning alleged fee-for-service claims to Medicare, Medicaid, and TRICARE. The company paid $10 million plus accrued interest and admitted to making payments for office space rentals that exceeded fair market value. Compliance with the 5-year CIA is ongoing, with potential monetary penalties and exclusion from federal healthcare programs for non-compliance.
• The company is currently responding to Civil Investigative Demands (CIDs), subpoenas, payor audits, and document requests for various matters relating to its laboratory operations. Some pending or threatened proceedings may involve substantial amounts and potential civil, criminal, or administrative fines or sanctions.

Related Party Transactions

• Leases office space from Frost Real Estate Holdings, LLC, an entity controlled by Dr. Phillip Frost (Chairman and CEO). An amendment in August 2024 decreased lease space and adjusted monthly payments.
• Issued $71.1 million aggregate principal amount of 2029 Convertible Affiliate Notes to Affiliate Purchasers, including Frost Gamma Investments Trust (controlled by Dr. Phillip Frost) and Dr. Jane H. Hsiao, in exchange for outstanding convertible promissory notes and accrued interest.
• Entered into an E-Commerce Distribution Agreement with NextPlat Corp, in which Dr. Frost owns more than a 20% interest, to launch an OPKO Health-branded online storefront in China and other Asian platforms.
• Entered into an Assignment and Assumption Agreement with Ruen-Hui Biopharmaceuticals, Inc., in which Dr. Hsiao owns more than a 10% interest, for an exclusive license agreement with Academia Sinica.
• Held investments in Zebra (29% ownership), ChromaDex Corporation (0.04%), Cocrystal Pharma, Inc. (2%), Non-Invasive Monitoring Systems, Inc. (0.5%), Eloxx Pharmaceuticals, Inc. (1%), BioCardia (0.1%), and LeaderMed Health Group Limited (47%), considered related party transactions due to executive management's ownership interests and/or board representation.
• Sold remaining investment in GeneDx (2.2% ownership as of December 31, 2024) during Q1 2025; Richard Pfenniger, a director, also sits on the GeneDx Board.
• BioReference procures products and services from subsidiaries of Danaher Corporation, where Dr. Elias Zerhouni (Vice Chairman and President) sits on the board, with payments totaling $2.3 million, $2.6 million, and $0.3 million to Beckman Coulter, Integrated DNA Technologies Inc., and Leica Microsystems Inc., respectively, in 2025.
• Reimburses Dr. Frost for Company-related use of an airplane owned by a company beneficially owned by Dr. Frost; no amounts reimbursed or accrued in 2025, but $131 thousand in 2024 and $79 thousand in 2023.

Stakeholder Impact

• **Shareholders**: Experienced significant dilution from the exchange of convertible notes for common stock. The stock repurchase program aims to return value, but the widening net loss and increased debt service could negatively impact share price and investment value. Concentration of ownership by directors, executive officers, and affiliated entities (49.61%) gives them significant influence over corporate decisions.
• **Employees**: Workforce reductions at BioReference (from ~3,300 to ~1,373) due to divestitures impacted a substantial number of employees. The company emphasizes competitive pay, benefits, and talent development, but the restructuring could affect morale and retention. Hired Employees from the divested business will receive comparable benefits and service credit with Buyer.
• **Customers**: Divestitures of BioReference's clinical diagnostics, reproductive health, women's health, and oncology businesses (excluding NY/NJ) mean changes in service providers for affected customers. The focus on core clinical and women's health testing in NY/NJ and national 4Kscore test aims to provide specialized, high-quality services. Transition services are in place to ensure continuity of care.
• **Suppliers**: Changes in BioReference's operations and cost-reduction initiatives could impact relationships and volumes with certain suppliers. The company's reliance on third-party manufacturers for pharmaceutical products means supplier performance is critical.
• **Creditors**: The issuance of $250 million in senior secured notes (2044 Notes) and $230 million in convertible senior notes (2029 Convertible Notes) significantly increased debt, impacting interest expense. The 2044 Notes are secured by Pfizer profit share payments, providing some collateral. The exchange of convertible notes for common stock reduced debt but increased equity.

Next Steps

• Aggressively develop ModeX's pipeline of next-generation multispecific antibodies and vaccines for cancer and infectious diseases.
• Advance internal candidates and progress clinical collaborations with Merck Sharp & Dohme LLC and Regeneron Pharmaceuticals, Inc.
• Actively pursue new licensing and collaboration opportunities leveraging proprietary technology platforms.
• Continue to support Pfizer's commercialization efforts to expand NGENLA's market share across more than 50 global markets.
• Support the pursuit of regulatory approvals for additional NGENLA indications, such as Small for Gestational Age (SGA).
• Drive continued adoption of Rayaldee in the U.S. and execute a global launch strategy with regional partners.
• Support strategic partner in the commercial launch of Rayaldee in Macau and regulatory submission in Mainland China.
• Scale high-margin specialty diagnostics, with a primary focus on increasing adoption of the 4Kscore test.
• Complete IND-enabling work and initiate a Phase 1 study for injectable OPK-88006 in 2026.
• Advance the oral OXM program in 2026 for the oral tablet formulation, with initial Phase 1 clinical data for injectable OXM expected in late 2026.
• Aim to file an IND application for the oral LA-PTH tablet in late 2026.
• Initiate a first-in-human Phase 1 clinical trial for MDX2003 in early 2026.
• Initiate the first-in-human clinical trial for MDX2301 tetravalent bispecific antibody (BARDA contract) in 2026.
• Continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in non-U.S. tax jurisdictions.

Key Dates

Recommendation

OPKO Health presents a mixed financial picture. While the company has made significant strategic moves through divestitures and new collaborations, aiming to streamline operations and focus on high-potential assets like NGENLA, Rayaldee, and ModeX's pipeline, the immediate financial results show a substantially wider net loss in 2025. This is largely driven by increased interest expense and a significant swing in other income, rather than core operational deterioration. The ongoing legal challenge with the Israel Tax Authority also represents a material contingent liability. Given the long-term potential of its pharmaceutical pipeline and strategic realignments, but balanced against current losses, increased debt, and regulatory uncertainties, a 'hold' recommendation is appropriate for seasoned investors. Further clarity on the commercial ramp-up of NGENLA, the success of ModeX's clinical programs, and the resolution of the tax dispute will be crucial for future re-evaluation.

Keywords

Pharmaceuticals, Diagnostics, Biotechnology, NGENLA, Somatrogon, Rayaldee, 4Kscore Test, ModeX Therapeutics, Multi-specific antibodies, Growth hormone deficiency, Secondary hyperparathyroidism, Prostate cancer, SEC filing, 10-K, Financial results, Clinical trials, Regulatory approval, Partnerships, Labcorp, Pfizer, Merck, Regeneron, Entera Bio, BARDA, Intellectual property, Healthcare regulation, Delaware corporation, NASDAQ